ストックスクリーナーアプリを入手
19.73
1.91%
0.3696
前日終値:
$19.36
開ける：
$19.21
24時間の取引高:
175.39K
Relative Volume:
1.33
時価総額：
$497.13M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+10.91%
1か月 パフォーマンス:
+21.79%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$19.21
$20.34
1週間の範囲:
$16.32
$20.34
52週間の値動き範囲:
$13.36
$20.34
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
LBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
19.65 | 487.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.05 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.75 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.71 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
902.23 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.60 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-06 | 開始されました | Leerink Partners | Outperform |
| 2025-10-06 | 開始されました | Piper Sandler | Overweight |
| 2025-10-06 | 開始されました | Stifel | Buy |
Lb Pharmaceuticals Inc (LBRX) 最新ニュース
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LB Pharmaceuticals Inc: Target Price Consensus and Analysts Recommendations | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Revenue and Earnings Analysts Forecasts Revisions | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Dividend historical data and projections - MarketScreener
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
LB Pharmaceuticals Appoints New Chief Commercial Officer - MSN
LB Pharmaceuticals amends lease to expand New York office space By Investing.com - Investing.com Australia
LB Pharmaceuticals Expands Lease at One Penn Plaza - TipRanks
LB Pharmaceuticals amends lease to expand New York office space - Investing.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event | LBRX SEC FilingForm 8-K - Stock Titan
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer - Investing.com Nigeria
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LB Pharmaceuticals names Kaya Pai Panandiker as CCO - The Pharma Letter
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer By Investing.com - Investing.com South Africa
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - The Manila Times
LB Pharmaceuticals, Inc Announces Appointment of Kaya Pai Panandiker as Chief Commercial Officer - MarketScreener
LB Pharmaceuticals - Nasdaq
LB Pharmaceuticals Reports Strong Q3 and Strategic Progress - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot - theheraldreview.com
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference - The Manila Times
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 - Investing.com Nigeria
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 By Investing.com - Investing.com South Africa
LBRX: IPO raised $327.8M; LB-102 advances with strong data; Q3 net loss narrows to $3.6M - TradingView
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates - The Manila Times
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
LB Pharmaceuticals, Inc. (LBRX) Stock News Today - TipRanks
LB Pharmaceuticals Inc Rings the Closing Bell - Nasdaq
LB Pharmaceuticals Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Novo-Backed MapLight Raises $258.9 Million in US IPO, Placement - Bloomberg.com
LB Pharmaceuticals Inc (LBRX) Recent Insider Transactions - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Latest Press Releases & Corporate News - Yahoo
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo! Finance Australia
Anna Eramo Net Worth (2025) - GuruFocus
Rebecca Luse Net Worth (2025) - GuruFocus
Lb Pharmaceuticals Inc (LBRX) 財務データ
Lb Pharmaceuticals Inc (LBRX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Lb Pharmaceuticals Inc (LBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
0.77%
0.84%
大文字化:
|
ボリューム (24 時間):